Our Management Team

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion.

Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co.

Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey.

Bharatt Chowrira, Ph.D., J.D. joined the Company as Chief Operating Officer in May 2008. His responsibilities include overseeing and managing all manufacturing, bioanalytical, and CMC operations across the Company, as well as corporate strategic functions including business development, licensing and marketing. He also serves as Chairman of Nektar India Pvt., Ltd.

Dr. Chowrira had previously served as Executive Director, Worldwide Licensing & External Research at Merck & Co. in San Francisco. He was responsible for identifying and evaluating R&D, licensing and partnering opportunities across all therapeutics areas, therapeutic modalities (including small molecules, biologics, vaccines and oligonucleotides), and technology platforms, throughout Asia. Dr. Chowrira was a key member of the team that established collaboration agreements between Merck and leading pharmaceutical firms in India such as Nicholas Piramal and Ranbaxy Labs. Dr. Chowrira also served as Vice President of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing.

Prior to Merck, Dr. Chowrira was a member of the executive management team at Sirna Therapeutics, a development-stage biopharmaceutical firm focused on the discovery and development of RNAi-based drugs that selectively target disease-causing genes and viruses. As Vice President at Sirna, he played a pivotal role in the restructuring and 2003 relaunch of the company, the development of its pipeline and intellectual property portfolio, and ultimately the sale of Sirna to Merck. He led the effort to identify research opportunities that resulted in corporate collaborations and licensing agreements with all of Sirna's partners, which included industry leaders such as GlaxoSmithKline, Allergan, and Eli Lilly & Co.

Dr. Chowrira earned his Ph.D. in Microbiology and Molecular Genetics from the University of Vermont and his J.D. degree from the College of Law at the University of Denver. He earned his M.S. in Molecular Virology from Illinois State University and his B.Sc. in Microbiology from the University of Agricultural Sciences, Bangalore, India.

Steve Doberstein joined Nektar in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of discovery research at Nektar. Dr. Doberstein brings over 17 years of experience in biotechnology research and development to the company. Prior to joining Nektar, Dr. Doberstein was Vice President of Research at XOMA where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics. Prior to that, Dr. Doberstein served as Vice President, Research at Five Prime Therapeutics, Inc, a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group. While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to that, Dr. Doberstein was Vice President, Research at Xencor, an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates. Before that, he also held a number of senior positions at Exelixis.

Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

Rinko Ghosh joined Nektar in May 2001 and has 20 years of experience in biopharmaceutical, healthcare and energy-related industries. He has completed over 40 major business transactions over his career and has worked in North America, Europe and Asia. His primary responsibilities at Nektar have included product and technology licensing, M&A, strategic planning, portfolio evaluation and alliance management. He is a member of the Executive Committee at Nektar and has been instrumental in closing significant revenue-generating transactions and building long-term alliances with AstraZeneca, Bayer, Novartis, Baxter, Roche, Pfizer, Affymax/Takeda, Covidien, UCB, Amgen, BMS, Schering-Plough and MAP Pharmaceuticals.

Prior to joining Nektar, he was engaged as Commercial Development Consultant at Aviron (now AstraZeneca/MedImmune) in Palo Alto, CA. Before Aviron, he was co-CEO of a biotechnology startup in Asia. Earlier, as a consultant with A.T. Kearney in San Francisco, CA and with Environ Corp, in Princeton, NJ, he worked with multi-national clients in healthcare and energy industries. Mr. Ghosh has been actively involved with non-profits, including the Asian Art Museum of San Francisco. He has served on several non-profit boards where has helped resolve issues related to board governance, general management and strategic planning.

Mr. Ghosh earned his M.B.A. from the Wharton School, University of Pennsylvania, his M.S. in Environmental Engineering from Vanderbilt University, and his B.S. in Chemical Engineering from the Indian Institute of Technology.

Gil M. Labrucherie joined Nektar in September 2005 as Vice President of Corporate Legal. Prior to joining Nektar, from October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open, Inc., where he was responsible for global corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for merger and acquisition transactions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati and Graham & James (DLA Piper Rudnick).

Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis.

Dr. Masuoka joined Nektar in August 2008 and has over 15 years of experience in clinical research and development. As Chief Medical Officer, she is instrumental in establishing Nektar’s clinical development strategy, and oversees all clinical and regulatory functions, including Clinical Development, Regulatory Affairs, Drug Safety, Clinical Pharmacology, Toxicology and Program Management.

Prior to Nektar, Lorianne was Vice President of Clinical Development at Five Prime Therapeutics where she led the advancement of a novel protein from research into clinical testing. Prior to that, Lorianne held senior leadership positions at Chiron and Berlex. At Chiron, she was Director of Clinical Development, Oncology, and led the efforts for a novel small molecule for gastrointestinal malignancies and an anti-CD40 antibody for hematologic malignancies. While at Berlex, she led efforts on Betaseron™ and a novel small molecule drug for multiple sclerosis.

Dr. Masuoka received her M.D. from the University of California, Davis, completed a Fellowship at Yale University and is board certified in Neurology.

John Nicholson was appointed Senior Vice President and Chief Financial Officer (CFO) of the company in December 2007. Mr. Nicholson reports to Nektar's President and Chief Executive Officer, Howard W. Robin. Previously, Mr. Nicholson was Senior Vice President, Corporate Development and Business Operations at Nektar. Prior to joining Nektar, he served in a number of leadership roles at Bayer Schering Pharma AG, including Vice President, Corporate Development and Treasurer of Schering Berlin Inc., President of Schering Berlin Insurance Company, President of Bayer Pharma Chemicals Inc., and President of Schering Berlin Capital Corporation. Mr. Nicholson also served as Treasurer of Berlex Inc.

Timothy A. Riley, Ph.D. joined the Company as Vice President, Research & Development in October 2005. His responsibilities include leading research operations and driving research strategy at Nektar. He is responsible for overseeing a number of key research functions at the company.

Dr. Riley had previously served as Senior Director Medicinal Chemistry at Chimerix Inc. in San Diego. He was responsible for directing medicinal chemistry as well as process development and clinical marker synthesis for their lead clinical candidate for smallpox, CMX001.

Prior to Chimerix, Dr. Riley was a Co-Founder and VP Operations and Chemistry for Oasis Biosciences Inc., a target validation company linking genes with disease. He was responsible for internal chemistry efforts, as well as, outsourced efforts. Dr. Riley was a key figure in all aspects of the Oasis Biosciences' operations.

Dr. Riley also served as VP of Chemistry at Genta. His team provided early work and support for Genta's lead product Genasense for melanoma.

Dr. Riley earned his Ph.D. in Organic Chemistry with a Biochemistry emphasis from Brigham Young University where he worked with Roland K. Robins, Ph.D., one of the grandfathers of nucleoside chemistry. He also earned his BS in Chemistry from Brigham Young University.

Dorian Rinella joined Nektar in April 2007. Her experience spans 16 years at biotechnology companies leading strategic and tactical aspects of human resource functions, including managing issues surrounding mergers and acquisitions. Prior to joining Nektar, Rinella headed the human resource programs at Sirna Therapeutics, where she was part of the diligence team during the acquisition process by Merck. She was also part of the team that started SUGEN and transitioned it from start-up through two acquisitions initially by Pharmacia and then by Pfizer Inc. In addition, she served as Vice President, Human Resources and Facilities at Kosan Biosciences and Corgentech/Anesiva.

Jillian B. Thomsen joined Nektar in March 2006 and was appointed Chief Accounting Officer in April 2008. Ms. Thomsen has 20 years of financial reporting and accounting experience. She currently oversees accounting, financial reporting, planning & analysis, Sarbanes-Oxley compliance, treasury and tax.

Prior to April 2008, she served as Vice President, Finance and Controller of Nektar. Before joining Nektar, Ms. Thomsen was Deputy Controller of Calpine Corporation from September 2002 to February 2006. From December 1990 to May 2002, Ms. Thomsen performed various roles with Arthur Andersen starting as a staff accountant and concluding as a senior manager. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.